Prolonged suppression of glucose metabolism causes insulin resistance in rat skeletal muscle.
To determine whether an impairment of intracellular glucose metabolism causes insulin resistance, we examined the effects of suppression of glycolysis or glycogen synthesis on whole body and skeletal muscle insulin-stimulated glucose uptake during 450-min hyperinsulinemic euglycemic clamps in conscious rats. After the initial 150 min to attain steady-state insulin action, animals received an additional infusion of saline, Intralipid and heparin (to suppress glycolysis), or amylin (to suppress glycogen synthesis) for up to 300 min. Insulin-stimulated whole body glucose fluxes were constant with saline infusion (n = 7). In contrast, Intralipid infusion (n = 7) suppressed glycolysis by approximately 32%, and amylin infusion (n = 7) suppressed glycogen synthesis by approximately 45% within 30 min after the start of the infusions (P < 0.05). The suppression of metabolic fluxes increased muscle glucose 6-phosphate levels (P < 0.05), but this did not immediately affect insulin-stimulated glucose uptake due to compensatory increases in other metabolic fluxes. Insulin-stimulated whole body glucose uptake started to decrease at approximately 60 min and was significantly decreased by approximately 30% at the end of clamps (P < 0.05). Similar patterns of changes in insulin-stimulated glucose fluxes were observed in individual skeletal muscles. Thus the suppression of intracellular glucose metabolism caused decreases in insulin-stimulated glucose uptake through a cellular adaptive mechanism in response to a prolonged elevation of glucose 6-phosphate rather than the classic mechanism involving glucose 6-phosphate inhibition of hexokinase.
Kim
J K
JK
Department of Physiology and Biophysics, University of Southern California School of Medicine, Los Angeles 90033, USA.
Youn
J H
JH
D000682:Amyloid / Q000494:pharmacology; D000818:Animals; D005217:Fat Emulsions, Intravenous / Q000494:pharmacology; D005947:Glucose / Q000037:antagonists & inhibitors* / Q000378:metabolism; D015309:Glucose Clamp Technique; D019298:Glucose-6-Phosphate / Q000378:metabolism; D006003:Glycogen / Q000378:metabolism; D006019:Glycolysis / Q000187:drug effects; D006493:Heparin / Q000494:pharmacology; D007328:Insulin / Q000494:pharmacology; D007333:Insulin Resistance; D058228:Islet Amyloid Polypeptide; D008297:Male; D018482:Muscle, Skeletal / Q000378:metabolism* / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
D000682:Amyloid; D005217:Fat Emulsions, Intravenous; D007328:Insulin; D058228:Islet Amyloid Polypeptide; D019298:Glucose-6-Phosphate; D006493:Heparin; D006003:Glycogen; D005947:Glucose